Trevogrumab (anti-myostatin) can help preserve lean mass during and after semaglutide-induced weight loss
New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, and in press at The Lancet shows that trevogrumab, which inhibits a protein that negatively regulates muscle mass, can reduce lean mass loss during semaglutide treatment by 50% compared with semaglutide and placebo.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Can we take the STING out of bone loss? Pathway presents potential treatment target for skeletal aging
-
Einstein’s general relativity equations: explained in plain English
-
Ozempic and Wegovy linked to rare risk of sudden vision loss
-
Parents of kids who need complex medical care at home tend to resolve frequent safety issues on their own, study finds
-
The ACOTAR x Knix Collection Just Dropped, And These Are the Best Pieces to Buy
-
Lasers and Doppler effect could personalize chemotherapy drug selection for cancer tumors
-
AI detects daily stress by analyzing routine smartphone behaviors
-
Global study exposes gaps in global endometriosis care guidelines